RxDoctor Payments Data

Christy Graves, MD

Internal Medicine · Slidell, LANPI 1013051036

Payments from drug & device makers

$8,588in general payments, 2019–2025

Across 577 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$937
  • Amgen$773
  • Pfizer$733
  • Merck$424
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$8,47899%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,588 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$69,153
Medicare patients
213
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin173$214,073
OzempicSemaglutide106$137,898
EliquisApixaban64$61,896
MounjaroTirzepatide37$56,757
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$51,843
LinzessLinaclotide26$34,664
FarxigaDapagliflozin Propanediol31$25,292
TradjentaLinagliptin32$23,573
JanuviaSitagliptin Phosphate31$21,681
QuliptaAtogepant12$20,130
CreonLipase/Protease/Amylase11$17,327
NexletolBempedoic Acid16$15,616
RestasisCyclosporine15$14,380
MyrbetriqMirabegron20$13,555
XareltoRivaroxaban17$10,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$218$237,646205 claims
Novo NordiskOzempic$937$137,898106 claims
AbbVieLinzess, Qulipta, Creon, Restasis, Savella$1,509$97,265132 claims
PfizerEliquis, Premarin$733$68,80185 claims
Lilly USA, LLCMounjaro$359$56,75737 claims
GSKTrelegy Ellipta$1,021$51,84362 claims
AstraZenecaFarxiga$159$25,29231 claims
MerckJanuvia$424$21,68131 claims
Esperion Therapeutics, Inc.Nexletol$73$15,61616 claims
Astellas Pharma US IncMyrbetriq$175$13,55520 claims
Johnson & JohnsonXarelto$78$10,29717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →